In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
ApexOnco Front Page
Recent articles
The private ADC company is being wound down.
Full data from Edge-Gastric are presented at ESMO.
The first TUB-040 data come just after Tubulis raised €308m.
The battle intensifies as LY4170156 matches torvuta-S with activity in FRα <25% expresers.
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.
